Key result
A single-dose, implant-based trivalent vaccine candidate produced antibodies against PCSK9, ApoB, and CETP at levels comparable to a three-dose injection schedule, reducing total plasma cholesterol.
Why the study?
Lowering plasma cholesterol is standard therapy for cardiovascular disease, but lifelong treatment and adverse effects call for improved therapeutic interventions.
Does a single-dose, implant-based trivalent VLP vaccine targeting PCSK9, ApoB, and CETP reduce plasma cholesterol levels compared to a three-dose injection schedule in a preclinical model?
Does a single-dose, implant-based trivalent VLP vaccine targeting PCSK9, ApoB, and CETP reduce plasma cholesterol levels compared to a three-dose injection schedule in a preclinical model?
A novel single-dose implant-based trivalent vaccine targeting PCSK9, ApoB, and CETP successfully lowers cholesterol in a preclinical model, offering a potential future alternative to lifelong lipid-lowering therapies.
Answers are grounded in this paper and cite their sources.
May support single-dose implant vaccines for lipid lowering in models; leaves open human translation and durability.
Cardiovascular disease is the number one cause of death globally. Lowering cholesterol levels in plasma is the mainstay therapy; however lifelong treatment and adverse effects call for improved therapeutic interventions. A trivalent vaccine candidate targeting proprotein convertase subtilisin/kexin‐9 (PCSK9), apolipoprotein B (ApoB), and cholesteryl ester transfer protein (CETP) is developed. Vaccine candidates are developed using bacteriophage Qβ‐based virus‐like particles (VLPs) displaying antigens of PCKS9, ApoB, and CETP, respectively. Vaccine candidate mixtures are formulated as slow‐release PLGA:VLP implants using hot‐melt extrusion. The delivery of the trivalent vaccine candidate via the implant produced antibodies against the cholesterol checkpoint proteins at levels comparable to a three‐dose injection schedule with soluble mixtures. The reduction in PCSK9 and ApoB levels in plasma, inhibition of CETP (in vitro), and total plasma cholesterol decrease is achieved. Altogether, a platform technology for a single‐dose multi‐agent proteins is presented.
No takes yet. Share an insight, caveat, or question.
Ortega‐Rivera et al. (2021) studied Cardiovascular disease. Trivalent vaccine candidate targeting PCSK9, ApoB, and CETP vs. Three-dose injection schedule with soluble mixtures was evaluated on Antibody production against cholesterol checkpoint proteins. A single-dose, implant-based trivalent vaccine candidate produced antibodies against PCSK9, ApoB, and CETP at levels comparable to a three-dose injection schedule, reducing total plasma cholesterol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: